<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870363</url>
  </required_header>
  <id_info>
    <org_study_id>200816535</org_study_id>
    <nct_id>NCT00870363</nct_id>
  </id_info>
  <brief_title>A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy</brief_title>
  <official_title>A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to find out how the immune system in the small intestines
      improves after taking antiretroviral (anti-HIV) medications. Biopsies (small snips of tissue)
      will be taken from the part of the intestines just below the stomach, and will be studied in
      the laboratory. The main purpose of this study is to measure the increase in the numbers of
      immune cells in the intestines to see if this number is related to the amount of medication
      that reaches the intestinal tissue, and the amount of virus that is still hiding there.

      Subjects are either normal control subjects without HIV or, are HIV positive and are about to
      start HIV medications. As part of this study, HIV positive patients will be randomized to
      receive one of three possible combinations of medications.

        1. maraviroc (Selzentry) in combination with 2 NRTIs (dual nucleoside reverse transcriptase
           inhibitor) or

        2. maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse
           transcriptase inhibitor) or

        3. efavirenz (Sustiva) in combination with 2 NRTIs (dual nucleoside reverse transcriptase
           inhibitor)

      Both Maraviroc and Raltegravir each represent new classes of medications in the way that they
      interfere with HIV making copies of itself. Maraviroc attaches to the surface of the T-cell
      that the virus uses to get into the cell and is therefore known as an entry inhibitor.
      Raltegravir blocks the virus from inserting itself into the DNA of the infected cell's
      nucleus and is therefore known as an Integrase Inhibitor. We hope to learn more about how
      antiretroviral drugs affect T cells and how immune function restores itself when HIV
      infection is treated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite improved survival, durable virologic suppression, and increases in peripheral CD4+
      T-cell counts in patients receiving potent antiretroviral therapy (ART), immune
      reconstitution remains incomplete as measured by a number of additional surrogate markers.
      Perhaps critically important among areas of apparent incomplete immune recovery is the
      gastrointestinal-associated lymphoid tissue (GALT), where CD4+ T-cells repopulate very slowly
      if at all. Several new classes of antiretrovirals (ART) have recently been approved by the
      FDA that offer potential advantages in terms of immune reconstitution and/or the kinetics
      viral suppression over traditionally available treatment regimens. Maraviroc is a new ART
      agent from a novel class of HIV inhibitors, entry inhibitors, that results in rapid
      suppression of HIV and recovery of peripheral CD4+ T-cells. This project proposes to examine
      whether volunteers receiving maraviroc recover GALT immune cells more completely that those
      taking comparator ART. Raltegravir is an integrase inhibitor that blocks incorporation of the
      proviral HIV DNA into the host chromosomes leading to more rapid declines in plasma HIV load
      than has previously been observed. This project proposes to examine whether volunteers
      receiving maraviroc or maraviroc plus raltegravir recover GALT immune cells more completely
      that those taking comparator ART. An additional attraction of the use of maraviroc and
      raltegravir together is that they may provide a potent combination that is also lipid neutral
      and thereby constitute a 'Heart friendly HAART' (Highly Active Antiretroviral Therapy).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Density of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Following Antiretroviral Therapy Regimen</measure>
    <time_frame>Baseline and nine months for 3 treatment cohorts and Baseline for the control group, which was only assessed at one time point</time_frame>
    <description>immunohistochemistry for CD3+/CD4+ cells counted manually within the lamina propria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma and Tissue Drug Levels in Volunteers at the Time of the Upper Endoscopy</measure>
    <time_frame>nine months</time_frame>
    <description>The reported drug level is for the primary ART agent for that cohort. For the maraviroc arm, maraviroc plasma and tissue levels are reported. For the maraviroc plus raltegravir arm, the raltegravir plasma and tissue levels are reported. For the efavirenz arm, the efavirenz plasma and tissue levels are reported. HIV negative controls were not on ART and did not have drug levels measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV DNA Per 10^6 Cells in Duodenal Tissue Versus PBMC by Drug Regimen Received</measure>
    <time_frame>Baseline and nine months</time_frame>
    <description>single-cell suspension of digested duodenal tissue and Ficol-Hypaque separated PBMC underwent HIV-DNA PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GALT CD4+ and CD8+ T-cell Subpopulations (na誰ve and Memory Subsets)</measure>
    <time_frame>nine months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte Immune Function and Activation at Two Time Points Approximately Nine Months Apart in GALT; and Four Timepoints (Month 0, 3, 6, and 9) in Peripheral Blood</measure>
    <time_frame>nine months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4+ T-cell Numbers by Treatment Regimen</measure>
    <time_frame>Baseline and nine months</time_frame>
    <description>peripheral absolute CD4+ T-cell counts increase from baseline to 9 months of cART by commercial assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution With Respect to Absolute Numbers of CD4+ T-cells, the Relative Proportion of T-cell Subpopulations in the Tissue, and Immune Activation to a Cohort of Normal Controls</measure>
    <time_frame>nine months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HIV-negative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)</intervention_name>
    <description>maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)</intervention_name>
    <description>maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Selzentry (maraviroc)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]</intervention_name>
    <description>efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Sustiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females ages 18 years to 60 years inclusive

          -  HIV positive (no anticipated antiretroviral therapy adjustments/changes)

          -  CD4 count greater than or equal to 50 cells/ml within 30 days of screening

          -  CCR5 tropism by Trofile ES(TM)

          -  Can be on secondary prophylaxis with a history of AIDS defining illness

          -  All females of child-bearing potential must agree to use barrier methods to prevent
             pregnancy or be abstinent from sexual activity while on study.

          -  willing to sign consent form

          -  HIV Negative individuals will also be recruited for this study as a Control Group

        Exclusion Criteria:

          -  allergy to peanuts or soya (maraviroc contains soya lecithin)

          -  abnormal coagulation parameters (PT greater than or equal to 1.2 ULN)

          -  thrombocytopenia (platelet count less than 50,000 within 6 weeks)

          -  known GI pathology

          -  contra-indications to upper endoscopy or conscious sedation

          -  anemia greater than grade 1

          -  any active acute opportunistic infection (OI) or therapy for acute OI within 30 days
             of entry into study

          -  positive pregnancy test

          -  aspirin, ibuprofen, warfarin, or other agents that interfere with the coagulation
             cascade taken within 1 week of endoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Asmuth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CARES Clinic</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM. Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Na誰ve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog. 2016 Mar 25;12(3):e1005540. doi: 10.1371/journal.ppat.1005540. eCollection 2016 Mar.</citation>
    <PMID>27015639</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <results_first_submitted>January 12, 2017</results_first_submitted>
  <results_first_submitted_qc>February 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2017</results_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV positive</keyword>
  <keyword>Gastrointestinal Associated Lymphoid Tissue (GALT)</keyword>
  <keyword>GALT Immune Reconstruction</keyword>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Maraviroc in Combination With 2 NRTIs</title>
          <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
        </group>
        <group group_id="P2">
          <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
          <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
        </group>
        <group group_id="P3">
          <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
          <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
        </group>
        <group group_id="P4">
          <title>HIV Negative Controls Not on ART</title>
          <description>HIV-negative</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maraviroc in Combination With 2 NRTIs</title>
          <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
        </group>
        <group group_id="B2">
          <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
          <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
        </group>
        <group group_id="B3">
          <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
          <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
        </group>
        <group group_id="B4">
          <title>HIV Negative Controls Not on ART</title>
          <description>HIV-negative</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="25" upper_limit="43"/>
                    <measurement group_id="B2" value="35" lower_limit="27" upper_limit="40"/>
                    <measurement group_id="B3" value="37" lower_limit="25" upper_limit="46"/>
                    <measurement group_id="B4" value="35" lower_limit="29" upper_limit="42"/>
                    <measurement group_id="B5" value="37" lower_limit="25" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 T-Cell count</title>
          <units>CELLS/MM^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="441" lower_limit="369" upper_limit="511"/>
                    <measurement group_id="B2" value="453" lower_limit="334" upper_limit="713"/>
                    <measurement group_id="B3" value="322" lower_limit="233" upper_limit="536"/>
                    <measurement group_id="B4" value="NA">not measured in the negative control cohort</measurement>
                    <measurement group_id="B5" value="436" lower_limit="283" upper_limit="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Density of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Following Antiretroviral Therapy Regimen</title>
        <description>immunohistochemistry for CD3+/CD4+ cells counted manually within the lamina propria</description>
        <time_frame>Baseline and nine months for 3 treatment cohorts and Baseline for the control group, which was only assessed at one time point</time_frame>
        <population>numbers represent an increase from baseline for the 3 treatment cohorts and represent the absolute value for the control group who were only measured at one timepjoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc in Combination With 2 NRTIs</title>
            <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
            <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O3">
            <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
            <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O4">
            <title>HIV Negative Controls Not on ART</title>
            <description>HIV-negative</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Density of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Following Antiretroviral Therapy Regimen</title>
          <description>immunohistochemistry for CD3+/CD4+ cells counted manually within the lamina propria</description>
          <population>numbers represent an increase from baseline for the 3 treatment cohorts and represent the absolute value for the control group who were only measured at one timepjoint.</population>
          <units>cells/mm^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="-44" upper_limit="92"/>
                    <measurement group_id="O2" value="89" lower_limit="51" upper_limit="127"/>
                    <measurement group_id="O3" value="119" lower_limit="-7" upper_limit="245"/>
                    <measurement group_id="O4" value="566" lower_limit="509" upper_limit="688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma and Tissue Drug Levels in Volunteers at the Time of the Upper Endoscopy</title>
        <description>The reported drug level is for the primary ART agent for that cohort. For the maraviroc arm, maraviroc plasma and tissue levels are reported. For the maraviroc plus raltegravir arm, the raltegravir plasma and tissue levels are reported. For the efavirenz arm, the efavirenz plasma and tissue levels are reported. HIV negative controls were not on ART and did not have drug levels measured.</description>
        <time_frame>nine months</time_frame>
        <population>HIV negative controls were not on ART and did not have drug levels measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc in Combination With 2 NRTIs</title>
            <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
            <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O3">
            <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
            <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O4">
            <title>HIV Negative Controls Not on ART</title>
            <description>HIV-negative</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma and Tissue Drug Levels in Volunteers at the Time of the Upper Endoscopy</title>
          <description>The reported drug level is for the primary ART agent for that cohort. For the maraviroc arm, maraviroc plasma and tissue levels are reported. For the maraviroc plus raltegravir arm, the raltegravir plasma and tissue levels are reported. For the efavirenz arm, the efavirenz plasma and tissue levels are reported. HIV negative controls were not on ART and did not have drug levels measured.</description>
          <population>HIV negative controls were not on ART and did not have drug levels measured.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>plasma primary ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="60.5" upper_limit="126.5"/>
                    <measurement group_id="O2" value="397" lower_limit="93.4" upper_limit="1131.3"/>
                    <measurement group_id="O3" value="2459" lower_limit="1485.7" upper_limit="5328.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>duodenal tissue primary ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.3" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.07" upper_limit="0.3"/>
                    <measurement group_id="O3" value="11.1" lower_limit="8.4" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV DNA Per 10^6 Cells in Duodenal Tissue Versus PBMC by Drug Regimen Received</title>
        <description>single-cell suspension of digested duodenal tissue and Ficol-Hypaque separated PBMC underwent HIV-DNA PCR</description>
        <time_frame>Baseline and nine months</time_frame>
        <population>HIV negative controls did not have HIV-DNA in blood or tissue</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc in Combination With 2 NRTIs</title>
            <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
            <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O3">
            <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
            <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O4">
            <title>HIV Negative Controls Not on ART</title>
            <description>HIV-negative</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV DNA Per 10^6 Cells in Duodenal Tissue Versus PBMC by Drug Regimen Received</title>
          <description>single-cell suspension of digested duodenal tissue and Ficol-Hypaque separated PBMC underwent HIV-DNA PCR</description>
          <population>HIV negative controls did not have HIV-DNA in blood or tissue</population>
          <units>copies/10^6 cells</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBMC HIV-DNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1709" lower_limit="-2845" upper_limit="-573"/>
                    <measurement group_id="O2" value="-2500" lower_limit="-4868" upper_limit="-132"/>
                    <measurement group_id="O3" value="-1330" lower_limit="-5354" upper_limit="2693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duodenal HIV-DNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" lower_limit="-40" upper_limit="8"/>
                    <measurement group_id="O2" value="-846" lower_limit="-1721" upper_limit="30"/>
                    <measurement group_id="O3" value="-325" lower_limit="-701" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in GALT CD4+ and CD8+ T-cell Subpopulations (na誰ve and Memory Subsets)</title>
        <time_frame>nine months</time_frame>
        <population>data were not collected due to the samples not being suitable for the epitopes being measured</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc in Combination With 2 NRTIs</title>
            <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
            <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O3">
            <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
            <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O4">
            <title>HIV Negative Controls Not on ART</title>
            <description>HIV-negative</description>
          </group>
        </group_list>
        <measure>
          <title>Change in GALT CD4+ and CD8+ T-cell Subpopulations (na誰ve and Memory Subsets)</title>
          <population>data were not collected due to the samples not being suitable for the epitopes being measured</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocyte Immune Function and Activation at Two Time Points Approximately Nine Months Apart in GALT; and Four Timepoints (Month 0, 3, 6, and 9) in Peripheral Blood</title>
        <time_frame>nine months</time_frame>
        <population>data were not collected due to inadequate sample volume for this complex experiment design</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc in Combination With 2 NRTIs</title>
            <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
            <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O3">
            <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
            <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O4">
            <title>HIV Negative Controls Not on ART</title>
            <description>HIV-negative</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocyte Immune Function and Activation at Two Time Points Approximately Nine Months Apart in GALT; and Four Timepoints (Month 0, 3, 6, and 9) in Peripheral Blood</title>
          <population>data were not collected due to inadequate sample volume for this complex experiment design</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CD4+ T-cell Numbers by Treatment Regimen</title>
        <description>peripheral absolute CD4+ T-cell counts increase from baseline to 9 months of cART by commercial assay</description>
        <time_frame>Baseline and nine months</time_frame>
        <population>peripheral CD4 T-cell counts were not measured in the HIV negative cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc in Combination With 2 NRTIs</title>
            <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
            <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O3">
            <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
            <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O4">
            <title>HIV Negative Controls Not on ART</title>
            <description>HIV-negative</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4+ T-cell Numbers by Treatment Regimen</title>
          <description>peripheral absolute CD4+ T-cell counts increase from baseline to 9 months of cART by commercial assay</description>
          <population>peripheral CD4 T-cell counts were not measured in the HIV negative cohort</population>
          <units>cells/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221" lower_limit="149" upper_limit="293"/>
                    <measurement group_id="O2" value="231" lower_limit="134" upper_limit="327"/>
                    <measurement group_id="O3" value="194" lower_limit="57" upper_limit="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution With Respect to Absolute Numbers of CD4+ T-cells, the Relative Proportion of T-cell Subpopulations in the Tissue, and Immune Activation to a Cohort of Normal Controls</title>
        <time_frame>nine months</time_frame>
        <population>data was not collected/analyzed due to complications in the assays for immune activation in the collected samples</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc in Combination With 2 NRTIs</title>
            <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
            <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O3">
            <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
            <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
          </group>
          <group group_id="O4">
            <title>HIV Negative Controls Not on ART</title>
            <description>HIV-negative</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution With Respect to Absolute Numbers of CD4+ T-cells, the Relative Proportion of T-cell Subpopulations in the Tissue, and Immune Activation to a Cohort of Normal Controls</title>
          <population>data was not collected/analyzed due to complications in the assays for immune activation in the collected samples</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during the 9 months of the study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc in Combination With 2 NRTIs</title>
          <description>maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
        </group>
        <group group_id="E2">
          <title>Maraviroc PLUS Raltegravir in Combination With 2 NRTIs</title>
          <description>maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor): maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
        </group>
        <group group_id="E3">
          <title>Efavirenz or Other NNRTI With 2 NRTIs</title>
          <description>efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]: efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician</description>
        </group>
        <group group_id="E4">
          <title>HIV Negative Controls Not on ART</title>
          <description>HIV-negative</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal intolerance</sub_title>
                <description>nausea due to medication that resolved with treatment modification</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuropsychiatric side effect</sub_title>
                <description>vivid dreams</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David M Asmuth</name_or_title>
      <organization>University of California Davis Medical Center</organization>
      <phone>(916) 734-8695</phone>
      <email>dasmuth@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

